Serum aminotransferase changes with significant weight loss: sex and age effects

Metabolism: Clinical and Experimental

Volumn 59, Issue 2, 2010, Pages 177-185

  Suzuki, Ayako ^a   Binks, Martin ^b,c   Sha, Ronald ^b,c   Wachholtz, Amy ^b,c,d   Eisenson, Howard ^b,c   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEHAVIOR MODIFICATION; DIET THERAPY; DISEASE MARKER; EXERCISE; FEMALE; HUMAN; LIPID METABOLISM; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBESITY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ALCOHOL DRINKING; BODY MASS INDEX; DIABETES COMPLICATIONS; DIET, CARBOHYDRATE-RESTRICTED; DIET, REDUCING; EXERCISE; HUMANS; LIVER DISEASES; LOGISTIC MODELS; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SEX FACTORS; SLEEP APNEA SYNDROMES; SMOKING; WEIGHT LOSS;

EID: 74249118635     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.06.030     Document Type: Article

References (37)

1. Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention. State-specific prevalence of obesity among adults-United States, 2005. JAMA 296 (2006) 1959-1960
2. Ogden C.L., Flegal K.M., Carroll M.D., et al. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288 (2002) 1728-1732
3. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352 (2005) 1138-1145
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
5. Adams L.A., and Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 82 (2006) 315-322
6. Kral J.G., Thung S.N., Biron S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135 (2004) 48-58
7. Andersen T., Gluud C., Franzmann M.B., et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12 (1991) 224-229
8. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22 (1998) 222-226
9. Srivastava S., and Younossi Z.M. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology 42 (2005) 490-492
10. Stratopoulos C., Papakonstantinou A., Terzis I., et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 15 (2005) 1154-1160
11. Mifflin M.D., St Jeor S.T., Hill L.A., et al. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 51 (1990) 241-247
12. Kral T.V., Roe L.S., and Rolls B.J. Combined effects of energy density and portion size on energy intake in women. Am J Clin Nutr 79 (2004) 962-968
13. Rolls B.J. The volumetrics eating plan (2005), HarperCollins Publishers, New York
14. Campos G.M., Bambha K., Vittinghoff E., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47 (2008) 1916-1923
15. Machado M., Marques-Vidal P., and Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006) 600-606
16. Thomas E.L., Potter E., Tosi I., et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis 195 (2007)
17. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 (2008) 100-110
18. Engl J., Sturm W., Sandhofer A., et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest 38 (2008) 238-244
19. Suzuki A., Lymp J., Sauver J.S., et al. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 26 (2006) 1209-1216
20. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
21. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
22. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
23. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
24. Fried S.K., Leibel R.L., Edens N.K., et al. Lipolysis in intraabdominal adipose tissues of obese women and men. Obes Res 1 (1993) 443-448
25. Lonnqvist F., Thorne A., Large V., et al. Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler Thromb Vasc Biol 17 (1997) 1472-1480
26. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40 (2004) 185-194
27. Lieber C.S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin Exp Res 23 (1999) 991-1007
28. Wang P.Y., Kaneko T., Wang Y., et al. Acarbose alone or in combination with ethanol potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen in rats. Hepatology 29 (1999) 161-165
29. Yoo J.S., Ning S.M., Pantuck C.B., et al. Regulation of hepatic microsomal cytochrome P450IIE1 level by dietary lipids and carbohydrates in rats. J Nutr 121 (1991) 959-965
30. Suzuki A., Sha R., Wachholtz A., Binks M., and Diehl A.M. Influence of impaired glucose tolerance, glucose control status, light to moderate alcohol consumption, and reduced carbohydrate diets on serum ALT change during rapid weight loss in the residential weight loss program. Hepatology 46 Suppl 741 (2007) 740A
31. Toroser D., and Sohal R.S. Age-associated perturbations in glutathione synthesis in mouse liver. Biochem J 405 (2007) 583-589
32. Vogt B.L., and Richie Jr. J.P. Glutathione depletion and recovery after acute ethanol administration in the aging mouse. Biochem Pharmacol 73 (2007) 1613-1621
33. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005) 384-387
34. Kristal B.S., Koopmans S.J., Jackson C.T., et al. Oxidant-mediated repression of mitochondrial transcription in diabetic rats. Free Radic Biol Med 22 (1997) 813-822
35. Kristal B.S., Jackson C.T., Chung H.Y., et al. Defects at center P underlie diabetes-associated mitochondrial dysfunction. Free Radic Biol Med 22 (1997) 823-833
36. Sudnikovich E.J., Maksimchik Y.Z., Zabrodskaya S.V., et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol (2007)
37. Scheffler E., Wiest E., Woehrle J., et al. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Investig 70 (1992) 263-268